Literature DB >> 109199

Histologic grade in advanced ovarian cancer.

R F Ozols, A J Garvin, J Costa, R M Simon, R C Young.   

Abstract

The histologic grade of epithelial ovarian tumors was found to be a major prognostic factor for survival in patients with advanced (stage III-IV) disease. In addition, a grading system based on cytologic detail (modified Broders' grades I-IV) identified groups with a differential response to chemotherapy. The overall improvement in survival observed with combination chemotherapy was related primarily to an increased survival of patients with grade II and III lesions. Although the survival of patients with grade I lesions was markedly better than for patients with grade IV lesions, in neither case was it influenced by the choice of single-agent or combination chemotherapy. In prospective clinical trials in advanced disease, modified Broders' grades should be included as a separate stratification factor.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 109199

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

Review 1.  Update in cancer chemotherapy: genitourinary tract cancer, Part 5: Ovarian cancer.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-05       Impact factor: 1.798

2.  Pathologic data of prognostic significance for remission induction in advanced ovarian carcinoma.

Authors:  B W Davis; A Goldhirsch; G W Locher; E Dreher; R Greiner; K Burki; K W Brunner
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

3.  Diagnosis and staging of ovarian cancer.

Authors:  A Pfleiderer
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

4.  Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.

Authors:  C Sessa; G Bolis; N Colombo; M D'Incalci; B Mermillod; I Valente; C Mangioni
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.